Epigenetic drivers of metalloproteinases and metastasis

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Metalloproteinases (MPs) are vital for physiological processes but their dysregulation contributes to cancer metastasis.
• Current MP inhibitor therapies face toxicity challenges, necessitating alternative strategies.
• Epigenetic mechanisms, like DNA methylation and histone modifications, tightly control MP expression.

Purpose of the Study:

• To explore the potential of targeting epigenetic regulators of MPs for cancer therapy.
• To investigate the specificity of epigenetically-driven MP expression in cancer cells.
• To evaluate this approach for preventing and treating metastatic disease.

Main Methods:

• Review of existing literature on metalloproteinases and epigenetic regulation in cancer.
• Analysis of studies investigating the role of epigenetic modifications in MP expression.
• Examination of preclinical and clinical data on targeting epigenetic pathways.

Main Results:

• Epigenetic regulation of MPs is crucial for maintaining homeostasis and development.
• Aberrant MP expression, driven by epigenetic changes, promotes cancer cell invasion and metastasis.
• Epigenetically-driven MP expression is often specific to cancer cells, offering a targeted therapeutic window.

Conclusions:

• Targeting epigenetic regulators of metalloproteinases presents a promising, cancer-specific therapeutic strategy.
• This approach could overcome the limitations of current MP inhibitors by reducing systemic toxicity.
• Modulating epigenetic activity may offer a novel avenue for preventing and treating metastatic cancers.